Rhythm Pharmaceuticals (RYTM) Tops Q2 EPS by 7c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance